Edition:
India

Castle Biosciences Inc (CSTL.OQ)

CSTL.OQ on NASDAQ Stock Exchange Global Market

19.11USD
10:38pm IST
Change (% chg)

$0.19 (+1.00%)
Prev Close
$18.92
Open
$19.00
Day's High
$19.50
Day's Low
$18.71
Volume
11,601
Avg. Vol
--
52-wk High
$24.73
52-wk Low
$17.11

Summary

Name Age Since Current Position

Daniel Bradbury

58 2014 Board Chairman

Derek Maetzold

56 2017 President, Chief Executive Officer, Founder, Director

Frank Stokes

Chief Financial Officer

Kristen Oelschlager

Vice President - Operations

Toby Juvenal

Vice President of Sales

Biographies

Name Description

Daniel Bradbury

Mr. Daniel Mark Bradbury is Board Chairman of the Castle Biosciences, Inc. He was an advisor to the company from 2008 until becoming a director. Mr. Bradbury is a life sciences executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm. Mr. Bradbury is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Biocon Limited, Corcept Therapeutics, Geron Corporation, and Intercept Pharmaceuticals, Inc. Mr. Bradbury also serves as a director for several private companies including DiaVacs, Inc., Equillium, Inc., Liquid Grids, Inc., Microdermis, Inc., NeuroVia, Inc., ProSciento, Inc. (formerly Profil Institute of Clinical Research, Inc.), Renova Therapeutics and Sensulin, Inc. Mr. Bradbury currently serves on the University of California San Diego’s Rady School of Management’s Advisory Council, the RAND Health Board of Advisors and the University of Miami’s Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

Derek Maetzold

Mr. Derek J. Maetzold is President, Chief Executive Officer, Founder and Director of Castle Biosciences, Inc. A leader in the biopharmaceutical industry for the past 25 years, Derek Maetzold founded Castle Biosciences in 2007 and has successfully overseen the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, with more in the pipeline. Derek founded the Company after a career of successive leadership roles at Encysive Pharmaceuticals, Schering Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals (now AstraZeneca) and Sandoz (now Novartis). Derek started in field sales, and has served in roles that span the disciplines of marketing, new product development, business development, and commercialization strategy. Previously, he served as Officer and Vice President, Marketing and Sales, at Encysive Pharmaceuticals. He attended George Mason University, where he received a B.S. in Biology, and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside. Derek is a published author, and a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals.

Frank Stokes

Mr. Frank Stokes is Chief Financial Officer of the Company. Frank Stokes has more than 20 years of experience in finance, including extensive experience leading capital formation for high-growth healthcare and life science companies. Most recently he was CFO of Hammock Pharmaceuticals where he assisted in the initial capitalization of the company as well as the acquisition of Hammock’s foundational drug delivery technology. Previously Frank served as a Senior Investment Banker at Leerink Partners, Robert W. Baird, and Wachovia Securities (now Wells Fargo Securities). He received a B.S. in business administration followed by MBA and J.D. degrees from the University of North Carolina at Chapel Hill.

Kristen Oelschlager

Ms. Kristen Oelschlager is Vice President of Operations for Castle Biosciences, Inc. Kristen Oelschlager joined the Company in 2008 as one of three initial employees, bringing more than 15 years of experience in clinical nursing, clinical operations services, and clinical research to the position. She oversees the operational aspects of the Company, including commercial/laboratory interface, clinical research and reimbursement. Prior to joining Castle, Kristen held senior roles in research operations, including the start-up and growth management of a multi-specialty clinical research department. She has extensive experience in process management under strict QA/QC/SOP. Kristen attended Purdue University, where she completed core nursing requirements concurrent to receiving an Associate of Science, Nursing from the Indiana Vocational Technical College. She has held Speaker’s Bureau appointments for Actelion Pharmaceuticals, Eli Lilly, and Encysive Pharmaceuticals, is a published author, and a co-inventor of a number of Castle Biosciences’ technologies.

Toby Juvenal

Mr. Toby Juvenal is Vice President of Sales of Castle Biosciences, Inc. Toby Juvenal has over 20 years of sales, sales management, and managed care experience in the pharmaceutical, biotechnology and diagnostics industries. In his current role, Toby leads the Company’s sales efforts, and has been instrumental in the acceleration of sales growth in recent years. Toby joined Castle Biosciences in 2008 as one of three initial employees. Prior to Castle, he held management positions at deCODE Genetics, Encysive Pharmaceuticals and Genzyme Pharmaceuticals. He began his career at Stuart Pharmaceuticals (now AstraZeneca). Toby attended the University of Florida where he received a B.S. in Marketing.

Basic Compensation

Options Compensation